Currently browsing tag

pfizer

Pfizer hikes U.S. prices for over 100 drugs on January 1

Pfizer Inc , which plans a $160-billion merger with Ireland-based Allergan Plc to slash its U.S. tax bill, on Jan. 1 raised U.S. prices for more than 100 of its drugs, some by as much as 20 percent, according to statistics compiled by global information services company Wolters Kluwer. Company spokesman Steven Danehy could not immediately confirm the remaining price increases, which were compiled by a unit of Wolters Kluwer Health and published in a research note by UBS Securities.

Pfizer’s quit-smoking drug not linked to depression or heart risks

By Kate Kelland LONDON (Reuters) – Pfizer's stop-smoking drug Chantix does not raise risks of heart attack or depression, contrary to previous reports, and should be recommended to more smokers wanting to quit, scientists said on Monday. In a study tracking 150,000 smokers in England for 6 months, researchers found that patients who took Chantix, known generically as varenicline and marketed as Champix in Europe, were no more likely to suffer a heart attack than those using nicotine replacement therapy or another quit-smoking drug.

Pfizer in $5 billion accelerated buyback deal with Goldman, Sachs & Co

(Reuters) – Drugmaker Pfizer Inc said it entered into an agreement with Goldman, Sachs & Co to buy back $5 billion of its stock. Pfizer said the accelerated share repurchase was assumed in the forecast for the full year it provided last month. Under the agreement, which forms a part of Pfizer's existing buyback authorization, about 150 million shares will be bought. The settlement is expected during or prior to the third quarter. Shares of the New York-based company closed at $33.06 on the New York Stock Exchange on Monday. …